Holen Sie sich die Stockscreener-App
5.205
2.71%
0.415
Schlusskurs vom Vortag:
$4.79
Offen:
$4.76
24-Stunden-Volumen:
614
Relative Volume:
0.00
Marktkapitalisierung:
$3.95M
Einnahmen:
$275.60K
Nettoeinkommen (Verlust:
$-8.33M
KGV:
-11.27
EPS:
-0.4619
Netto-Cashflow:
$-5.40M
1W Leistung:
-20.52%
1M Leistung:
+1,294%
6M Leistung:
+980.84%
1J Leistung:
+505.39%
1-Tages-Spanne:
$4.76
$4.76
1-Wochen-Bereich:
$4.5101
$6.36
52-Wochen-Spanne:
$0.2201
$7.69
Nexalin Technology Inc Stock (NXL) Company Profile
Firmenname
Nexalin Technology Inc
Sektor
Branche
Telefon
(832) 260-0222
Adresse
1776 YORKTOWN, HOUSTON
Compare NXL vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NXL
Nexalin Technology Inc
|
4.76 | 3.97M | 275.60K | -8.33M | -5.40M | -0.4619 |
ABT
Abbott Laboratories
|
106.17 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.84 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
272.97 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.62 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.51 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Nexalin Technology Inc Aktie (NXL) Neueste Nachrichten
Nexalin Technology Announces Key Executive Leadership Departure - TipRanks
Nexalin Technology registers to sell 5.75M shares of common stock for holders - TipRanks
Multi-million-share resale could boost Nexalin (NASDAQ: NXL) share count - Stock Titan
Greenlight Ventures Discloses Investment at Nexalin Technology with 5.6% Stake - TradingView
Stock-for-deal investor steps in at Nexalin (NASDAQ: NXL) - Stock Titan
Nexalin Technology (NASDAQ: NXL) Announces Carolyn Shelton's Exit with $20,000 Bonus and Accelerated Stock Option Vesting - kalkinemedia.com
Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to - Yahoo Finance
Carolyn Shelton exits Nexalin as Senior VP; separation terms include bonus and option vesting - TradingView
Nexalin Technology, Inc. Announces Resignation of Carolyn Shelton from Senior Vice President of Quality, Regulatory, and Clinical Affairs, Effective August 28, 2026 - marketscreener.com
Nexalin Technology Inc. (NASDAQ: NXL) Share Price, NXL Stock News, NXL Share Price & Updates - Kalkine
NXL Should I Buy - intellectia.ai
Nexalin Technology approves 1-for-30 reverse stock split By Investing.com - Investing.com Nigeria
Nexalin Technology Announces 1-for-30 Reverse Stock Split to Maintain Nasdaq Compliance - Quiver Quantitative
Nexalin Technology approves 1-for-30 reverse stock split - Investing.com
Nexalin Technology Raises Liquidity via Short-Term Note - TipRanks
Nexalin Technology Issues $1.17 Million OID Note for $1.0 Million Proceeds - TradingView
Nexalin Announces Capital Raise and Flexible Equity Facility - TipRanks
Nexalin Technology Raises $750,000 in Registered Direct Offering - Minichart
Nexalin Technology Announces $0.75M Direct Offering and $15M Equity Purchase Facility With Alumni Capital - TradingView
Nexalin (NXL) EPS and Revenue: EPS Does Not Reach the Reported Estimate in the Available Record; The Share Price Sheds 2.06% in Latest TradingEPS Guidance Update - dars.gov.et
Nexalin Faces New Nasdaq Equity Deficiency, Delisting Risk - The Globe and Mail
Nexalin Technology Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nexalin Technology earnings missed, revenue fell short of estimates By Investing.com - Investing.com South Africa
Nexalin Technology earnings missed, revenue fell short of estimates - Investing.com
Nexalin Technology (NXL) Edges Higher at $0.36 as Neurostimulation Stock Holds Key SupportIceberg Order - dars.gov.et
Nexalin Technology, Inc. 2Q 2026: Revenue $12.16K, EPS ($0.11) — 10-Q Summary - TradingView
Nexalin Technology (NXL) flags going concern risk as losses mount and Nasdaq warns - Stock Titan
Nexalin Technology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Nexalin Technology | 8-K: Current report - Moomoo
Nexalin Technology Inc (NXL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nexalin Technology Inc (NXL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Nexalin Technology Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Nexalin Expands and Extends Houston Headquarters Lease Commitment - The Globe and Mail
Nexalin Technology Inc (NXL) Institutional Confidence - TradingKey
Nexalin Appeals Nasdaq Delisting Following Compliance Shortfalls - TipRanks
Nexalin Technology Received Notice of Delisting - TradingView
Nexalin Technology Inc (NXL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NXL|Nexalin Technology Inc|Price:0.353|Chg%:+0.014 - TradingKey
Nexalin Technology Inc (NXL) Cash Flow - TradingKey
Nexalin Technology Inc (NXL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NXL|Nexalin Technology Inc|Price:0.500|Chg%:+0.019 - TradingKey
Nexalin Technology Inc (NXL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nexalin Technology Inc (NXL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NXL|Nexalin Technology Inc|Price:0.481|Chg%:+0.013 - TradingKey
NXL Q1 2026 Earnings: EPS Misses Estimates as Company Advances Non-Invasive Neuromodulation PipelineNew Analyst Coverage - vinanet.vn
Nexalin Technology, Inc. Revenue Breakdown – NASDAQ:NXL - TradingView
NXL Q1 2026 Earnings: EPS Misses Estimates by 8.91% While Shares Edge HigherQuarterly Profit Report - vinanet.vn
NXL Q1 2026 Earnings: Loss Per Share Misses Estimates as Development Continues Without Revenue - vinanet.vn
Nexalin Technology (NXL) Registration filing Summary - Quartr
Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life - True North Radio Network
Nexalin Technology Inc. (NXL) Q1 2026 Earnings: EPS Miss Slightly Wider Than Anticipated; Stock Rises on No Revenue UpdateEarnings Per Share - vinanet.vn
Finanzdaten der Nexalin Technology Inc-Aktie (NXL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):